0.13
-0.0101(-7.22%)
Currency In USD
Address
2001 Junipero Serra Boulevard
Daly City, CA 94014
United States of America
Phone
415 655 4168
Sector
Healthcare
Industry
Biotechnology
Employees
21
First IPO Date
October 09, 2020
| Name | Title | Pay | Year Born |
| Dr. Javier Szwarcberg M.D., M.P.H. | Chief Executive Officer & Director | 951,850 | 1970 |
| Dr. Kirk Ways M.D., Ph.D. | Chief Medical Officer & Director | 46,480 | 1952 |
| Mr. Michael G. Grey | Executive Chairman | 70,000 | 1953 |
| Mr. Samir M. Gharib CPA, M.B.A. | President & Chief Financial Officer | 683,626 | 1982 |
| Ms. P. J. Ramtin | Senior Vice President of Business Operations | 0 | N/A |
| Ms. Heidi Petersen M.P.H. | Senior Vice President of Regulatory & Quality | 0 | N/A |
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.